Accolade (Nasdaq: ACCD), a US-based healthcare company, announced on Thursday that it has named Elizabeth Nabel, MD and Jeff Brodsky as its new directors.
Dr Nabel is the executive vice president for strategy at ModeX Therapeutics. She served for eleven years as the president of Brigham and Women's Hospital. She directed the National Heart, Lung, and Blood Institute of the National Institutes of Health and also serves on the boards of directors of Moderna, a pharmaceutical company, and Medtronic, a medical device company.
Brodsky is the vice chairman at Morgan Stanley and member of its operating committee. He has over 30 years of experience at Morgan Stanley and held various leadership roles across the human resources function. He also serves on the Safe Horizon board of directors and is an executive in residence at the University of Michigan's Ross School of Business, where he earlier served on the advisory board.
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system
Bonesupport shifts CERAMENT V review to FDA's De Novo pathway
Neola Medical secures US patent for disposable lung monitoring probes
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
Aetna to launch generative AI-powered conversational experience
Maxx Orthopedics Receives FDA 510(k) Clearance for Its Libertas® Bipolar Hip System
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix